20 Result(s)

Article

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways

Rhabdomyosarcoma (RMS) is the most frequent form of pediatric soft-tissue sarcoma. It is divided into two main subtypes: ERMS (embryonal) and ARMS (alveolar). Current treatments are based on chemotherapy, surg...

J. Vial, P. Huchedé, S. Fagault, F. Basset, M. Rossi, J. Geoffray… in Cell Death Discovery (2020)

Article

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences...

F. G. M. Verspoor, M. J. L. Mastboom, G. Hannink, R. G. Maki… in Scientific Reports (2019)

Article

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe...

J. Khalifa, M. Ouali, L. Chaltiel, S. Le Guellec, A. Le Cesne, J-Y Blay… in BMC Cancer (2015)

Article

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells.

A Adenis, I Ray-Coquard, A Italiano, E Chauzit, B Bui-Nguyen… in British Journal of Cancer (2013)

Article

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS).

A L Cesne, I Judson, R Maki, F Grosso, S Schuetze, M V Mehren… in British Journal of Cancer (2013)

Article

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS.

P A Cassier, A Lefranc, E Y Amela, C Chevreau, B N Bui… in British Journal of Cancer (2013)

Article

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor rec...

S Sleijfer, T Gorlia, C Lamers, H Burger, J-Y Blay, A Le Cesne… in British Journal of Cancer (2012)

Article

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma

We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue sarcoma (STS) patients treated with first-line chemotherapy.

N Penel, M V Glabbeke, S Mathoulin-Pelissier, I Judson… in British Journal of Cancer (2011)

Article

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response to treatment are unk...

A Dufresne, F Bertucci, N Penel, A Le Cesne, B Bui… in British Journal of Cancer (2010)

Article

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region

Preliminary data indicate that the molecular epidemiology of localised gastrointestinal stromal tumour (GIST) may be different from that of advanced GIST. We sought to investigate the molecular epidemiology of...

P A Cassier, F Ducimetière, A Lurkin, D Ranchère-Vince… in British Journal of Cancer (2010)

Article

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

Fibromatosis comprises distinct clinical entities, including sporadic extra-abdominal fibromatosis, which have a high tendency for recurrence, even after adequate resection. There are no known molecular biomar...

J Dômont, S Salas, L Lacroix, V Brouste, P Saulnier, P Terrier… in British Journal of Cancer (2010)

Article

Prognosis and predictive value of KIT exon 11 deletion in GISTs

KIT exon 11 mutations are observed in 60% of gastrointestinal stromal tumours (GIST). Exon 11 codes for residues Tyr568 and Tyr570, which play a major role in signal transduction and degradation of KIT. Our aim w...

J-B Bachet, I Hostein, A Le Cesne, S Brahimi, A Beauchet… in British Journal of Cancer (2009)

Article

Incidence and prognostic value of tumour cells detected by RT–PCR in peripheral blood stem cell collections from patients with Ewing tumour

To retrospectively evaluate the incidence of tumour cell contamination of peripheral blood stem cell (PBSC) collections and to correlate these data with the clinical outcome after high-dose chemotherapy (HDCT)...

J Vermeulen, S Ballet, O Oberlin, M Peter, G Pierron… in British Journal of Cancer (2006)

Article

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome

Circulating autoantibodies to self-antigens overexpressed by cancer cells are common in cancer patients. As specific proteins are expressed during neoangiogenesis, a similar phenomenon might occur with particu...

T Bachelot, D Ratel, C Menetrier-Caux, D Wion, J-Y Blay… in British Journal of Cancer (2006)

Article

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that t...

T Bachelot, I Ray-Coquard, C Menetrier-Caux, M Rastkha, A Duc… in British Journal of Cancer (2003)

Article

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

A risk model for febrile neutropenia (FN) after conventional cytotoxic chemotherapy, based on early (day 5) lymphopenia and the dose of chemotherapy, has been described. A risk index based on parameters availa...

I Ray-Coquard, C Borg, Th Bachelot, C Sebban, I Philip… in British Journal of Cancer (2003)

Article

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colo...

T Bachelot, F Gomez, P Biron, I Ray-Coquard, P Soler-Michel… in British Journal of Cancer (2002)

Article

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

1–5% of cancer patients treated with cytotoxic chemotherapy die within a month after the administration of chemotherapy. Risk factors for these early deaths (ED) are not well known. The purpose of this study w...

I Ray-Coquard, H Ghesquière, T Bachelot, C Borg, P Biron… in British Journal of Cancer (2001)

Article

Osteosarcoma

T Philip, J Y Blay, M Brunat-Mentigny, C Carrie, P Chauvot… in British Journal of Cancer (2001)

Article

Renal cell carcinoma induces interleukin 10 and prostaglandin E₂ production by monocytes

Immunotherapy with interleukin 2 (IL-2) is not an effective anti-cancer treatment in the majority of patients with renal cell carcinoma (RCC), suggesting that the activation of cytotoxic T cells or NK cells ma...

C Ménétrier-Caux, C Bain, M C Favrot, A Duc, J Y Blay in British Journal of Cancer (1999)